ALMS (Alumis Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ALMS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | SRINIVAS AKKARAJU | Director | MIXED | — | — |
| 2026-08-05 | Sanam Pangali | Chief Legal Officer | Sell | — | — |
| 2026-08-05 | Roy C. Hardiman | Chief Business & Strategy Ofcr | Sell | — | — |
| 2026-08-05 | John R. Schroer | Chief Financial Officer | Sell | — | — |
| 2026-08-05 | Jorn Drappa | Chief Medical Officer | Sell | — | — |
| 2026-08-05 | Mark Christopher Bradley | Chief Development Officer | Sell | — | — |
| 2026-08-05 | David M Goldstein | Chief Scientific Officer | Sell | — | — |
| 2026-07-08 | Sanam Pangali | Chief Legal Officer | MIXED | — | — |
| 2026-07-02 | SRINIVAS AKKARAJU | Director | A | — | — |
| 2026-07-02 | Zhengbin Yao | Director | A | — | — |
| 2026-07-02 | Sapna Srivastava | Director | A | — | — |
| 2026-07-02 | Patrick Machado | Director | A | — | — |
| 2026-07-02 | LYNN A. TETRAULT | Director | A | — | — |
| 2026-05-27 | Jorn Drappa | Chief Medical Officer | M | — | — |
| 2026-04-03 | James B. Tananbaum | Director | J | — | — |
| 2026-04-03 | Foresite Labs, LLC | 10%+ Owner | J | — | — |
| 2026-04-03 | Foresite Capital Opportunity Fund V, L.P. | 10%+ Owner | J | — | — |
| 2026-01-28 | Martin Babler | President, CEO and Chairman | A | — | — |
| 2026-01-28 | Mark Christopher Bradley | Chief Development Officer | A | — | — |
| 2026-01-28 | Roy C. Hardiman | Chief Business & Strategy Ofcr | A | — | — |
| 2026-01-28 | John R. Schroer | Chief Financial Officer | A | — | — |
| 2026-01-28 | Jorn Drappa | Chief Medical Officer | A | — | — |
| 2026-01-28 | David M Goldstein | Chief Scientific Officer | A | — | — |
| 2026-01-28 | Sanam Pangali | Chief Legal Officer | A | — | — |
| 2026-01-13 | SRINIVAS AKKARAJU | Director | Buy | — | — |
| 2026-01-12 | James B. Tananbaum | Director | Buy | — | — |
| 2026-01-12 | Foresite Labs, LLC | 10%+ Owner | Buy | — | — |
| 2026-01-12 | Foresite Capital Fund V, L.P. | 10%+ Owner | Buy | — | — |
| 2025-12-09 | SRINIVAS AKKARAJU | Director | Buy | — | — |
| 2025-12-04 | SRINIVAS AKKARAJU | Director | Buy | — | — |
| 2025-12-01 | SRINIVAS AKKARAJU | Director | Buy | — | — |
| 2025-11-25 | Foresite Labs, LLC | 10%+ Owner | Buy | — | — |
| 2025-11-25 | James B. Tananbaum | Director | Buy | — | — |
| 2025-11-25 | Foresite Labs Fund I, L.P. | 10%+ Owner | Buy | — | — |
| 2025-11-24 | SRINIVAS AKKARAJU | Director | Buy | — | — |
| 2025-11-19 | SRINIVAS AKKARAJU | Director | Buy | — | — |
| 2025-11-19 | James B. Tananbaum | Director | Buy | — | — |
| 2025-11-19 | Foresite Labs Affiliates 2021, LLC | 10%+ Owner | Buy | — | — |
| 2025-11-19 | Foresite Capital Opportunity Management V, LLC | 10%+ Owner | Buy | — | — |
| 2025-11-17 | SRINIVAS AKKARAJU | Director | Buy | — | — |
| 2025-08-01 | Patrick Machado | Director | A | — | — |
| 2025-08-01 | Sapna Srivastava | Director | A | — | — |
| 2025-08-01 | LYNN A. TETRAULT | Director | A | — | — |
| 2025-08-01 | Zhengbin Yao | Director | A | — | — |
| 2025-08-01 | SRINIVAS AKKARAJU | Director | A | — | — |
| 2025-07-31 | Jorn Drappa | Chief Medical Officer | A | — | — |
| 2025-07-31 | Martin Babler | President, CEO and Chairman | A | — | — |
| 2025-07-31 | John R. Schroer | Chief Financial Officer | A | — | — |
| 2025-07-31 | Derrick Richardson | SVP, People and Culture | A | — | — |
| 2025-07-31 | Mark Christopher Bradley | Chief Development Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 15,139,707 | — |
| — | Director | 8,145,966 | — |
| — | Director | 4,247,670 | — |
| — | 10%+ Owner | 2,614,215 | — |
| — | 10%+ Owner | 2,542,003 | — |
| — | 10%+ Owner | 2,542,003 | — |
| — | Director | 2,029,046 | — |
| — | 10%+ Owner | 1,960,337 | — |
| — | 10%+ Owner | 1,960,337 | — |
| — | 10%+ Owner | 1,176,470 | — |
| — | 10%+ Owner | 1,176,470 | — |
| — | Chief Business & Strategy Ofcr | 214,163 | — |
| — | President, CEO and Chairman | 109,454 | — |
| — | Chief Development Officer | 68,559 | — |
| — | Chief Medical Officer | 56,892 | — |
| — | SVP, People and Culture | 42,800 | — |
| — | Chief Scientific Officer | 39,964 | — |
| — | Chief Legal Officer | 33,796 | — |
| — | Director | 27,082 | — |
| — | Chief Financial Officer | 24,718 | — |
| — | Director | 16,104 | — |
| — | Director | 10,617 | — |
| — | Chief Legal Officer | 9,747 | — |
| — | Director | 3,553 | — |
| — | Director | 3,553 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALMS quote page; the site-wide leaderboard is on the insider transactions hub.